Background-The purpose of this study was to evaluate the frequency and temporal trends in use of transradial access (TRA) for percutaneous coronary intervention (PCI) in ST-segment-elevation myocardial infarction (STEMI). 
T he use of radial artery access during cardiac catheterization and percutaneous coronary intervention (PCI) has become much more frequent in the past several years, increasing from <2% of PCI cases in 2006 to >15% of PCI cases in 2012 according to National Cardiovascular Data Registry data. 1, 2 Transradial access (TRA) currently accounts for at least 1 of every 6 PCIs performed in clinical practice. The advantages of TRA compared with traditional transfemoral access (TFA) have been widely described and include a lower incidence of bleeding and vascular complications, 3, 4 and acute kidney injury, 5 as well as a reduction in major cardiovascular events including death according to some studies. 6, 7 These come without significant increases in fluoroscopy time or contrast volume in the hands of experienced operators 2, 8 although this is likely dependent on operator volume. 9 Bleeding complications after PCI are associated with significantly increased rates of morbidity, mortality, and healthcare expenditure. 10 In patients with ST-segment-elevation myocardial infarction (STEMI), who are at high risk for bleeding complications, TRA has been shown to reduce the incidence of major bleeding 7, [11] [12] [13] [14] without increased door-to-balloon times. 15 Furthermore, a small body of randomized data suggests a possible survival benefit in association with radial PCI. This has led to a 2012 European Society of Cardiology Class IIa (LOE: B) Radial Access in Patients Undergoing PCI recommendation for preferred radial access in primary PCI for STEMI in the hands of an experienced operator. 16 Although TRA is increasingly being adopted for elective PCI in the United States, there are limited data on the prevalence and clinical effectiveness of radial access for primary PCI in contemporary interventional practice. Accordingly, we evaluated the trends in the usage for TRA for PCI in STEMI in a large real-world cohort, The Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2).
Methods
The BMC2 collaborative is a prospective, multicenter registry including all 47 nonfederal hospitals in the state of Michigan. The registry collects detailed demographic, clinical, and procedural data including in-hospital outcomes from all PCI cases; further details have been previously described. 17, 18 The University of Michigan Institutional Review Board has waived the need for approval of studies performed on the data collected by the BMC2 registry.
Patients undergoing PCI between January 1, 2010, and December 31, 2013, were included in the cohort. The indication for PCI was defined as PCI for STEMI, non-STEMI (NSTEMI), unstable angina, or non-acute coronary syndrome (ACS) and then separated into binary groups STEMI and all others, including NSTEMI, unstable angina, and non-ACS. Patients presenting with shock or after cardiac arrest were excluded because of significantly worse outcomes in this small subset of patients and the increased likelihood of requiring mechanical support that is almost always inserted via the femoral approach.
The rate of radial access utilization by quarter was estimated separately for patients presenting with STEMI and those with other coronary artery disease (CAD) presentations. Estimated quarterly TRA rates were plotted along with least square linear fit lines, and linear regression models were used to compare estimated linear growth rates in the use of radial access between cohorts of patients presenting with STEMI versus other presentations. Patients were then divided into deciles of predicted risk of postprocedural bleeding estimated from baseline clinical characteristics using a previously described risk prediction algorithm published by Mehta et al, 19 and the rate of TRA use was compared between deciles of predicted risk using Fisher exact and Cochrane-Armitage tests. To assess whether the relationship between TRA use and predicted bleeding risk in our cohort varied over time, a date by predicted bleeding risk interaction term was included in a logistic regression model with TRA use for each procedure as the outcome and CAD presentation, predicted bleeding risk, and date as main effects predictors.
Propensity-matching and multivariate conditional logistic regression was then used to assess the association between TRA and clinical outcomes among patients presenting with STEMI. STEMI TRA patients were matched on a 1:1 basis without replacement to STEMI TFA patients using a propensity score obtained from a logistic regression model including available baseline clinical and demographic characteristics. Matched pairs were required to have propensity score values within a 0.25 SD caliper. The propensity score matching procedure is described in detail in Statistical Appendix in the Data Supplement. In-hospital outcomes including major bleeding, transfusion requirement, vascular complication, stroke, contrast-induced nephropathy, and mortality were evaluated using multivariate conditional logistic regression models adjusting for baseline covariates included in propensity matching and accounting for the matched design in the propensity-matched sample. 20 Given significant variability in operator volume for TRA, the individual operators in the cohort were divided into groups based on volume. Operators who performed >150 transradial PCIs during the study period were considered high-volume operators. To assess whether the potential beneficial effects of TRA were more likely to be realized by operators with greater experience, multivariate logistic regression was used in a propensity-matched data set including patients with both STEMI and other CAD presentations, but with exact matching required for STEMI versus all other CAD presentations. The fitted regression model included all-cause mortality as the outcome adjusting for baseline covariates and including TRA by operator volume (>150 versus ≤150) interaction term.
In-hospital death was defined as death from either cardiac or noncardiac cause before discharge; major bleeding was defined as drop in hematocrit by ≥10% or drop in hemoglobin by ≥3g/dL; transfusion was defined as any transfusion of blood products regardless of the number of units transfused, and contrast-induced nephropathy was defined as impairment in renal function resulting in ≥0.5 mg/dL absolute increase in serum creatinine from baseline. 21 Vascular complication was defined as the postprocedural occurrence of any of the following: pseudoaneurysm, arteriovenous fistula, femoral neuropathy, hematoma at the access site requiring transfusion or prolonged hospital stay or causing a drop in hemoglobin of >3g/dL, retroperitoneal hematoma, acute arterial thrombosis or loss of limb.
Wilcoxon rank-sum tests were used to compare continuous measures, and Fisher exact tests were used to compare categorical measures. A significance level of α=0.05 was used to declare statistical significance, and all reported P values are 2 sided. All analysis was performed using R statistical software, version 3.0.1.
Results
Between January 1, 2010, and December 31, 2013, 127 993 PCI procedures were performed in 124 306 patients at 47 hospitals participating in the BMC2 registry. Of these, 516 were performed via an access site other than the radial or femoral artery (ie, brachial artery) and were excluded from the cohort. CAD presentation was missing for 40 procedures and a further 4709 procedures performed in patients presenting with cardiogenic shock or cardiac arrest were excluded. Of the patients excluded because of shock or arrest, 3002 presented with STEMI, 1397 with NSTEMI or unstable angina, and 310 with a non-ACS indication. After excluding these cases, a total of 122 728 procedures in 119 949 patients were included in the analysis, with
WHAT IS KNOWN
• The use of transradial arterial access (TRA) during percutaneous coronary intervention is increasing in the United States.
• TRA has been shown to decrease complication rates and improve outcomes compared with transfemoral access in percutaneous coronary intervention.
WHAT THE STUDY ADDS
• The rate of TRA adoption is slower for patients with ST-segment-elevation myocardial infarction than for those presenting with other, less emergent, indications (ie, non-ST-segment-elevation myocardial infarction, unstable angina, and non-acute coronary syndrome).
• Percutaneous coronary intervention for ST-segmentelevation myocardial infarction performed via TRA was associated with less bleeding but no mortality difference compared with transfemoral access.
• Despite lower rates of bleeding complications, there is a strong negative correlation between the predicted risk of bleeding and actual use of TRA in patients undergoing contemporary percutaneous coronary intervention. via TRA for a total of 17 912 transradial procedures. Baseline demographics are presented in Table 1 . Patients underwent PCI via TRA in 8.3% of cases when the presenting diagnosis was STEMI, compared with 15.6% of cases when the presenting diagnosis was NSTEMI, unstable angina, or non-ACS.
Over the time period studied, the rate of TRA for PCI increased across all groups (Figure 1) . By the end of 2013, TRA was used for PCI in >30% of cases for indications other than STEMI with a slope of ≈2% increase per quarter. Although the frequency of use of TRA in STEMI increased steadily as well, the rate of increase was significantly slower at 1.2% per quarter than it was for other indications (P<0.001).
In STEMI, periprocedural glycoprotein 2b3a inhibitors were used more often in cases performed via TFA, and bivalirudin was used less often in TFA compared with TRA. Cases performed via TFA had higher median predicted bleeding risks than those performed via TRA (2.3% versus 2.1%; P<0.001 for STEMI and 1.1% versus 1.0%; P<0.001 for other indications) and there was a strong negative correlation between predicted risk of bleeding and the use of TRA (Figure 2 ). This trend persisted throughout the time period studied (P=0.45 for date by risk interaction), despite more frequent overall utilization of TRA.
The observed major bleeding rate was slightly lower than the National Cardiovascular Data Registry-algorithm predicted bleeding rates for both TRA (1.49% versus 2.1%) and TFA (2.06% versus 2.3%) STEMI cases. After adjusting for baseline variables including age, sex, medical history, and PCI status through propensity matching and multivariate regression, there was no significant difference in in-hospital mortality for patients with STEMI undergoing PCI via TRA compared with TFA (Table 2) . However, when PCI for STEMI was performed via TRA, there were lower incidences of bleeding (P<0.001), transfusion (P=0.032), and vascular complications (P=0.001) with no difference in the rate of postprocedural contrast-induced nephropathy (P=0.087) or cerebrovascular accident (P=0 0.427). There was a nonsignificant trend toward lower mortality for PCI in STEMI via TRA compared with TFA (1.25% versus 2.33%; P=0.175).
There were 372 individual operators at the 47 hospitals included in the cohort; the median number of TRA PCIs per operator was 11 (interquartile range, 1-57) over the study period. Thirty-eight operators (10.2%) performed >150 TRA PCIs over the study period and were considered high-volume operators. The exploratory regression model fitted to assess whether any beneficial effect of TRA on mortality improved with operator experience produced an odds ratio of 0.65 for TRA versus TFA for high-volume operators, compared with a odds ratio of 0.96 for TRA versus TFA in lower volume (ie, <150 TRA PCI cases) operators; however, neither the estimated main effect for TRA nor the TRA by high-volume interactions were statistically significant (P>0.2 for both).
Discussion
In our study of >122 000 patients undergoing PCI in the state of Michigan from 2010 to 2013, we observed a significant increase in the rate of TRA. Patients selected for TRA were on average younger, had higher body mass index, higher ejection fractions, better baseline renal function, and lower predicted bleeding risks than those selected for TFA. Although we excluded those patients in shock or after cardiac arrest, it seems clear from our data that sicker patients are, in general, still preferentially being selected for TFA.
There are several plausible explanations for this, the most likely of which relates to operator volume and perceived level of success; especially in time-critical settings such as STEMI. In 2011, Ball et al 22 In a study of patients undergoing PCI for STEMI in the state of New York from 2009 to 2010, there was considerable heterogeneity in TRA utilization among hospitals within the state. Although the use of TRA was not associated with a significant difference in mortality when compared with TFA as a whole, when isolating those higher-volume centers that used TRA in >10% of cases, a trend was noted toward lower mortality for TRA. 24 As PCI centers become more familiar with TRA and its use becomes increasingly more frequent for PCI, it is likely that outcomes may continue to improve as well. Recently published data from the National Cardiovascular Data Registry CathPCI registry found that access site bleeding decreased over time from 2009 to 2012 for all centers using TRA for PCI. When stratifying centers by rates of TRA adoption, however, the decline in bleeding outcomes was significantly larger at hospitals with more rapid adoption of TRA than with those with little or no change in TRA utilization. 25 Superior outcomes, including lower rates of bleeding and at times improved in-hospital mortality, have been widely reported for TRA than for TFA in primary PCI for STEMI and include multiple randomized trials, 4, 11, 13 several recent meta-analyses, 12, [26] [27] [28] and a large volume of observational data. 1, 14, 29, 30 The majority of randomized data showing clinical benefit from TRA PCI have been from high-volume, experienced providers. For example, the Trial Comparing Radial and Femoral Approach in Primary Percutaneous Coronary Intervention (STEMI-RADIAL) randomized patients to either TRA or TFA after presenting with STEMI to high-volume operators performing at least 200 PCIs per year with at least 80% of these via TRA. In this setting, significantly lower rates of major bleeding and access site complications were observed in the TRA cohort with no difference in 6-month mortality. 11 The RIVAL trial showed improved outcomes including mortality in patients undergoing TRA compared with TFA for STEMI although this outcome was not seen in patients undergoing TRA for other indications. 31 However, in a subgroup analysis separating patients by both operator and center volume, high-volume centers (defined at >142 radial PCI/y per operator) were associated with significantly better TRA outcomes, including death, MI, stroke, or non-coronary artery bypass graft-related bleeding compared with TFA, whereas lower-volume radial centers were not, 32 a trend that was also seen in our findings.
Our data showed improved clinical outcomes associated with TRA for patients presenting with STEMI, including lower rates of bleeding and vascular complications; with no differences in complications such as stroke or contrast-induced nephropathy, and no difference in mortality. However, we also observed that TFA was preferentially used not only just in sicker patients as previously mentioned but also in patients with higher predicted bleeding risks, a paradox given the widely reported benefits of TRA for bleeding complications and our own data. The underutilization of TRA in settings where it may be of the most help, such as in patients with higher bleeding risks, is not unique to our data and a 2013 report by Wimmer et al 33 noted similar results. Assessed by a novel prediction model for TFA complications, patients undergoing PCI between 2008 and 2011 at 5 institutions in Massachusetts who were at this highest risk for vascular access site complications (including access site bleeding requiring transfusion or causing large hematoma, retroperitoneal or other arteriotomy-related bleeding, or death from vascular cause) via TFA were found to be the least likely to receive TRA for PCI.
Interestingly, our data also showed that in STEMI settings, patients undergoing PCI via TFA were more likely to receive periprocedural GP 2b3a inhibitor and less likely to receive bivalirudin, a decision that may play a role in the increased bleeding rates seen in the TFA group 34 and may also reflect the sicker overall patient population selected for TFA.
Given the rapid rate of adoption for TRA for patients presenting for PCI for NSTEMI, unstable angina, or non-ACS indications, another possible explanation for our findings is that providers are selectively choosing more stable, less timecritical cases for TRA to become more familiar and comfortable with the technique. As comfort and confidence increases, so may the use of TRA in more acute settings like STEMI.
There are several limitations to our findings. First, our study includes nonrandomized patients and is solely an observational study representing a real-world cohort across 47 hospitals in the state of Michigan with highly variable rates of TRA utilization. Although operators were stratified by volume level, there was a relatively small proportion of providers (ie, 4.6%) who performed >150 TRA PCIs and only 4 sites that performed >40% of their PCIs via TRA during the study period, significantly limiting statistical power.
Another confounding variable in our findings is the role of access-site crossover. According to both the National Cardiovascular Data Registry and our BMC2 database, the access site used for PCI is the location of the access at the actual moment of PCI, a definition that does not account for previous failed access sites at other anatomic locations. The BMC2 database did not begin tracking the rate of failed access and secondary access-site crossover until early 2014, and thus these data are not incorporated into our current cohort. In addition, several of the vascular complication outcomes reported in our study, including retroperitoneal hematoma and femoral neuropathy, are specific to TFA and would not be seen with TRA, limiting the applicability of this clinical end point. Likewise, TRA-specific vascular complications including *Adjusting for age, sex, smoking status, hypertension, dyslipidemia, family history of coronary artery disease, previous myocardial infarction, previous heart failure, previous valve surgery, previous percutaneous coronary intervention, previous CABG, height, weight, current dialysis, cardiovascular disease, peripheral artery disease, chronic lung disease, diabetes mellitus, and percutaneous coronary intervention status (elective, urgent, emergent, and salvage).
forearm hematoma, compartment syndrome, radial artery occlusion, and avulsion are not tracked within the BMC2 database and were thus not included as outcomes. Finally, the operator's choice of periprocedural anticoagulation was not individually tracked or standardized in our data set, a decision that may affect the rates of bleeding complications.
Conclusions
This large, observational study of over 120 000 patients undergoing PCI in Michigan showed significant increases in the rate of transradial arterial access for PCI over the past 4 years. TRA adoption is slower for patients with STEMI than for those with other, less emergent, indications. Although TRA PCI is associated with lower rates of bleeding, transfusion, and vascular complications, there is a strong negative correlation between the risk of bleeding and TRA utilization. This treatment paradox suggests that TRA may be underutilized in settings where it may provide the most benefit and provides an area for further investigation and quality improvement efforts.
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